1
项与 Recombinant vaccinia virus expressing 5 transgenes(University Hospital, Basel, Switzerland) 相关的临床试验Active Specific Intranodal Immunotherapy With a Recombinant Vaccinia Virus Expressing Three Melanoma Associated Epitopes and Two Costimulatory Molecules, Followed by Immunization With Synthetic Melanoma Associated Epitopes. A Phase I/II Trial in Patients With Stages IIb to IV Melanoma
The purpose of this study is to assess intranodal immunotherapy in locally advanced to metastatic melanoma patients (American Joint Committee on Cancer [AJCC] stages IIb to IV).
For this, the investigators capitalize on their previous melanoma clinical trial (published by Zajac P et al in Human Gene Ther 2003) and take advantage of a proprietary recombinant vaccinia virus (replication inactivated) expressing 5 minigenes: 3 melanoma associated antigens and 2 costimulatory molecules. Immunization with the recombinant vaccinia virus is followed by 3 boosts with soluble, synthetic melanoma associated antigens.
The patients are immunized intranodally (groin lymph node) under ultrasonographic guidance in an outpatient clinic. The protocol foresees 2 cycles of immunotherapy for alternate weeks and lasts 15 weeks.
100 项与 Recombinant vaccinia virus expressing 5 transgenes(University Hospital, Basel, Switzerland) 相关的临床结果
100 项与 Recombinant vaccinia virus expressing 5 transgenes(University Hospital, Basel, Switzerland) 相关的转化医学
100 项与 Recombinant vaccinia virus expressing 5 transgenes(University Hospital, Basel, Switzerland) 相关的专利(医药)
100 项与 Recombinant vaccinia virus expressing 5 transgenes(University Hospital, Basel, Switzerland) 相关的药物交易